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Background: Nerve ligation injury in rats produces a pain syndrome that includes mechanical allodynia. Intrathecal 
administration of cholinesterase inhibitors or adenosine receptor agonists have anti-allodynic effects in this model. 
Therefore, we tested the interaction between intrathecal neostigmine and N
6-cyclohexyladenosine (CHA) in a rat 
behavioral model of neuropathic pain. 
Methods: Male Sprague-Dawley rats were prepared with tight ligation of the spinal nerves for producing allodynia 
and with a lumbar intrathecal catheter for drug administration. Allodynia thresholds for hindpaw withdrawal against 
mechanical stimuli were assessed and converted to percent maximal possible effect. Neostigmine (0.3-10 μg) and 
CHA (0.03-3 μg) were administered to obtain the dose-response curves and the 50% effective dose (ED50). Equal 
fractions (1/2, 1/4 and 1/8 ED50s) of the two drugs were administered to establish the ED50 of neostigmine-CHA 
combination. Side effects were also assessed. The drug interaction was evaluated by isobolographic and fractional 
analyses. 
Results: Neostigmine, CHA, and the neostigmine-CHA combination dose-dependently produced anti-allodynia 
effects. Side effects such as sedation and motor weakness were similar in the three groups. In the isobolographic 
analysis, the experimental ED50 for the combination of neostigmine-CHA lay far below and to the left of the 
theoretical additive line. Fractional analysis indicated that the total combination fraction of the two drugs was 0.39. 
Conclusions: Intrathecal co-administration of neostigmine and CHA showed a synergistic anti-allodynia effect.   
(Korean J Anesthesiol 2010; 59: 39-44)
Key Words:  Allodynia, Drug interaction, Intrathecal injection, N
6-cyclohexyladenosine, Neostigmine.
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Introduction
    Peripheral nerve injury may produce a pain syndrome 
consisting of hyperalgesia, spontaneous pain, and mechanical 
and thermal allodynia. Unilateral tight ligation of the fifth and 
sixth lumbar (L5 and L6) spinal nerves in rats produces signs 
that appear representative of neuropathic pain [1]. The spinal 
nerve ligation (SNL) model displayed profound and long-lasting 
mechanical allodynia that can be reduced by sympathectomy 
[2]. Cholinesterase inhibitors and adenosine receptor agonists 
produce an anti-allodynic effects in rats with a nerve ligation 
injury [3,4]. Intrathecal (IT) administration of neostigmine, 
a cholinesterase inhibitor, has an anti-nociceptive effect [3]. 
IT injection of N
6-cyclohexyladenosine (CHA), an adenosine 
A1 receptor agonist, also produces anti-nociception in the 
neuropathic rat model [5]. Although the synergistic interaction 
of spinal neostigmine and adenosine has been demonstrated 
in a rat model of postoperative hypersensitivity [6], there have 
been no studies on the anti-allodynic interaction between 
spinal neostigmine and CHA in the SNL model. Therefore, 
we assessed the drug interaction using isobolographic and 
fractional analyses between IT neostigmine and CHA in the 
SNL model. 
Materials and Methods
Animal preparation
    The experiments were performed under a protocol approved 
by the Animal Care Committee. Male Sprague-Dawley rats 
(weight 160-180 g) were housed individually in a temperature-
controlled (21 ± 1
oC) vivarium and allowed to acclimate for 
three days in a 12/12-h day/night cycle.
Surgical procedures
    To create the SNL model, a surgical procedure was performed 
according to the method described by Kim and Chung [1]. 
Under the enflurane anesthesia, the left L5 and L6 spinal nerves 
were isolated and ligated tightly with 6-0 black silk distal to 
the dorsal root ganglion and proximal to the formation of the 
sciatic nerve. The IT catheter was implanted if the rat showed 
a withdrawal threshold of 4.0 g or less by postoperative day 7, 
which indicated mechanical allodynia. The implantation of 
IT catheter was performed as previously described [7]. Under 
enflurane anesthesia, a polyethylene tube (PE-10) was passed 
8.5 cm caudally from the cisterna magna to the rostral edge of 
the lumbar enlargement and externalized through the skin. 
Only animals without the evidence of neurologic deficit after 
the operation were included in this study. Rats were kept 
in individual vivaria and allowed to recover for 5 days after 
catheter implantation. 
Behavioral measures
    Behavioral testing was done at the same time during the day 
(9:00 AM to 4:00 PM). Rats were placed in individual plastic 
cages with wire mesh bottoms and allowed to acclimate for 
20 min. The mechanical threshold was measured by applying 
a von Frey filament (Stoelting, Wood Dale, IL, USA) vertically 
to the midplantar surface of the hindpaw ipsilateral to the 
nerve ligation injury until a positive sign for pain behavior was 
elicited. According to the method described by Chaplan et al. 
[8], a series of eight calibrated von Frey filaments (0.41, 0.70, 
1.20, 2.00, 3.63, 5.50, 8.50, and 15.10 g) was applied serially to 
the paw in ascending order of strength with sufficient force to 
cause gentle bending against the paw and held for six seconds. 
A sharply withdrawal or paw flinching was considered a positive 
response. The mechanical stimulus producing a 50% likelihood 
of withdrawal was determined by using the up-down method. 
Measurements were taken before and 15, 30, 60, 90, and 120 
min after the IT administration of each drug. Side effects were 
simply evaluated by observing the presence of sedation and 
motor weakness. Severe sedation was defined as a significant 
decrease in spontaneous activity and a loss of the orienting 
reflex to light touch. Motor weakness was assessed by observing 
abnormal ambulation, abnormal weight bearing, or righting 
and stepping reflexes. 
Drugs
    The following drugs were used in this study: neostigmine 
bromide (Research Biochemicals International [RBI], Natick, 
MA, USA), CHA (RBI), and pirenzepine (RBI). All drugs were 
dissolved in normal saline and were administered intrathecally 
with a microinjection syringe (Hamilton Co., Reno, NV, USA) 
over a 60 second interval in a volume of 10 μl, followed by a 10-
μl flush. 
Experimental paradigm
 The first series of experiments defined the dose-response 
curves of intrathecal administered neostigmine (0.3, 1, 3, and 
10 μg) and CHA (0.03, 0.1, 0.3, 1, and 3 μg) from the mean 
percent maximal possible effect (%MPE) to establish the 
ED50s of two drugs. In the second series of experiments, ED50 
fractions (1/2, 1/4, and 1/8) of each drug were administered 
concurrently to establish the ED50 of neostigmine-CHA 
combinations. Thereafter, the drug interactions were evaluated 
by isobolographic and fractional analyses. In the third series of 41 www.ekja.org
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experiments, to identify a possible mechanism of the interaction 
between neostigmine and CHA, muscarinic antagonist 
pirenzepine 3 μg was administered intrathecally 10 min before 
the injection of both drugs. 
Isobolographic and fractional analysis
    To determine whether the drug interaction between 
neostigmine and CHA is additive or synergistic, an equal dose 
ratio isobolographic analysis was conducted by using the 
method of Tallarida and Murray [9]. The theoretical additive 
combination dose was calculated by the method described 
by Tallarida et al. [9,10]. The experimental ED50 values were 
compared with the theoretical additive ED50 values as defined 
by the theoretical additive line. The theoretical additive ED50 
point lies on a line connecting the ED50 values of the individual 
drugs. The experimentally derived value that lies below and 
to the left of the theoretical additive line is considered to be 
synergistic, whereas value that lies above and to the right of the 
line demonstrates an antagonistic interaction. 
    Fractional analysis was performed to obtain a value for 
describing the magnitude of the drug interaction. A total 
fraction was calculated with the following formula: (ED50 dose 
of neostigmine in combination / ED50 value for neostigmine 
alone) + (ED50 dose of CHA in combination / ED50 value for 
CHA alone). A value near 1 implies an additive interaction, and 
value less than 1 indicates a synergistic interaction [11].
Data analysis and statistics
    The peak drug effects were recorded and then used to 
calculate %MPE values. These %MPE values were plotted 
versus the log dose for dose response data. The withdrawal 
threshold data from von Frey filament testing were obtained as 
the actual threshold in grams and converted to %MPE values by 
the following formula: %MPE for anti-allodynia = ([post-drug 
threshold - baseline threshold] / [15 g - baseline threshold]) × 
100. The cut-off value was defined as a stimulus intensity of 15 g 
for the mechanical threshold (i.e., %MPE = 100). 
    Data are presented as mean ± SEM or 95% confidence intervals 
(CIs). The ED50 values, slopes, and 95% CIs were determined 
using a dose-response analysis. Variances and their 95% CIs for 
the theoretical additive ED50 were calculated from the variances 
of each component administered alone. The difference 
between the theoretical additive point and the experimentally 
derived ED50 was compared by a Student t-test. The effect of 
drugs on mechanical allodynia was tested by one-way analysis 
of variance for repeated measures followed by Dunn’s post	
hoc test. The difference between the agonistic effect and the 
antagonistic effect was tested by Mann-Whitney Rank Sum test. 
P value < 0.05 was considered statistically significant. 
Results
Baseline response characteristics
    After spinal nerve ligation, all rats displayed a significant 
decrease in mechanical threshold (from 15 g to the range of 1 
to 4 g) necessary to evoke a brisk withdrawal response in the 
injured hindpaw in response to von Frey filament stimulation.
Anti-allodynic effects of drugs
    IT administration of neostigmine, CHA, and their combin-
ation produced a dose-dependent anti-allodynic effect (Fig. 1). 
The maximal anti-allodynia effects occurred within 30 min, and 
then decreased gradually to baseline with the passage of time. 
The patterns of time-effect course were similar in all groups (data 
not shown). 
Drug interaction 
    The ED50 values and slopes of neostigmine, CHA, and their 
combination are described in Table 1. The dose-response curve 
of the combination group was shifted to the left and steeper 
compared drug alone (Fig. 1). Isobolographic analysis indicated 
a synergistic interaction between neostigmine and CHA (Fig. 2). 
The experimentally determined mixture ED50 (± SEM) was 0.07 
Fig. 1. Dose-response curves from the peak effects of percent 
maximal possible effect (%MPE) for anti-allodynia in the neostig-
mine, N
6-cyclohexyladenosine, and their combination subgroups. 
These curves show a dose-dependent anti-allodynic effect. Data are 
expressed as mean ± SEM. Doses (μg) are represented logarithmically 
on the x axis and peak %MPE of each group is represented on the y 
axis. CHA: N
6-cyclohexyladenosine, Neo: neostigmine, Neo-CHA: 
combination of neostigmine and N
6-cyclohexyladenosine. *P < 0.05 
compared with baseline value in each group. 42 www.ekja.org
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μg (±0.016) for neostigmine and 0.02 μg (±0.004) for CHA. The 
theoretical additive ED50 was calculated to be 0.18 μg (±0.04) 
for neostigmine and 0.05 μg (±0.01) for CHA. The experimental 
value of neostigmine-CHA combination was significantly less 
than the calculated additive value (P < 0.05). The total fraction 
for the neostigmine-CHA combination was 0.39, indicating a 
synergistic interaction (Table 2).
Antagonistic study
    Pretreatment with the muscarinic M1 antagonist pirenzepine 
significantly reduced the anti-allodynic effect of IT neostigmine-
CHA combination (P < 0.05, Fig. 3).
Side effects
    Some rats in all groups displayed a mild to moderate sedation 
and motor weakness, but no severe sedation or motor weakness. 
There was no apparent increase in the incidence and severity 
of side effects in the combination group (Table 3). After IT 
admini  stration of either 10 μg of neostigmine or 3 μg of CHA, a 
mode  rate motor weakness was observed in two rats (one in the 
neosti  gmine group and one in the CHA group).
Discussion
    After peripheral nerve injury, a harmless, low-intensity 
mechanical stimulus can elicit pain behavior mediated by 
the activation of low threshold mechanoreceptors subserved 
Table 1. ED50s and Slopes of Neostigmine, N
6-cyclohexyladenosine 
and Their Combination
ED50 (95% CI) (μg) Slope (95% CI)
Neo (n = 23)
CHA (n = 42)
Neo-CHA (n = 30)
0.37 μg (0.17-0.80 μg)
0.10 μg (0.07-0.15 μg)
0.09 μg (0.06-0.14 μg)
37.5 (23.5-51.5)
47.7 (36.9-58.5)
 89.0 (34.3-143.8)
CHA: N
6-cyclohexyladenosine, ED50: 50% effective dose, Neo: 
neostigmine, Neo-CHA: combination of neostigmine and N
6-
cyclohexyladenosine. 
Fig. 2. Isobologram for the interaction between intrathecal 
neostigmine and N
6-cyclohexyladenosine. Horizontal and vertical 
bars indicate SEM. The diagonal line connecting two 50% effective 
dose (ED50) points is the theoretical additive line. The ED50 point A 
is calculated from the ED50 values and 95% confidence intervals of 
each drug. The experimental ED50 point B lies far below the line of 
additivity, indicating significant synergism. CHA: N
6-cyclohexyla-
denosine, Neo: neostigmine. *P < 0.05 compared with theoretical 
ED50 point A. 
Table 2. ED50s and 95% Confidence Intervals (or SEM) for Intra-
thecally Administered Neostigmine, N
6-cyclohexyladenosine and 
Their Combination 
Agent
Neo CHA Sum of
ED50 
fraction
Fraction 
of ED50
Intrathecal
dose (μg)
Fraction 
of ED50
Intrathecal
dose (μg)
Neo
(n = 23)
CHA
(n = 42)
Neo-CHA
(n = 30)
1.00
-
0.19
0.37
(0.17-0.80)
-
0.07
(± 0.016)
-
1.00
0.2
-
0.10
(0.07-0.15)
0.02
(± 0.004)
1.00
1.00
0.39
CHA: N
6-cyclohexyladenosine, ED50: 50% effective dose, Neo: 
neostigmine, Neo-CHA: combination of neostigmine and N
6-
cyclohexyladenosine. 
Fig. 3. Antagonistic study of the combination subgroup by pirenzepine. 
Pretreatment with the muscarinic M1 receptor antagonist, 
pirenzepine, decreases the anti-allodynic effect. Data are expressed 
as mean ± SEM. ED50 = 50% effective dose, Neo-CHA: combination 
of neostigmine and N
6-cyclohexyladenosine, Pir: pirenzepine. 
*P < 0.05 compared with baseline value in each group. 
†P < 0.05 
compared with pirenzepine pretreatment group. 
‡P < 0.05 compared 
with control group.43 www.ekja.org
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by large myelinated primary afferents [12]. The mechanisms 
underlying this miscoding of low-threshold afferent information 
could result from spontaneous activity in the dorsal root 
ganglion [13], trans-synaptic degenerative changes of the dorsal 
horn neurons [14], abnormal sympathetic innervation of the 
dorsal root ganglion neurons [15], and sprouting of numerous 
large myelinated sensory fibers into lamina II, an area where 
they do not normally terminate [16].
    The spinal cholinergic muscarinic system is important for 
the regulation of nociception. Cholinesterase inhibitors or 
muscarinic receptor agonists produce an anti-allodynic effect 
that can be blocked by muscarinic antagonists [3]. Furthermore, 
autoradiography and immunohistochemical studies have 
shown a high density of spinal muscarinic receptors in the 
superficial laminae, areas which were involved predominantly 
with the processing of afferent pain impulses [17,18]. Muscarinic 
agonists may work by direct postsynaptic hyperpolarization of 
the dorsal horn neuron by opening G protein-coupled inwardly 
rectifying K
+ channels [19] or activation of muscarinic receptors 
on GABAergic interneurons to stimulate GABA release, which 
then reduces glutamate release onto lamina II neurons [20]. 
Either way, the spinal cholinergic muscarinic system is intrinsic 
and regulates afferent input. 
    The spinal muscarinic system tonically inhibits noxious 
mechanical, but not noxious thermal, transmission [21]. Here, 
IT neostigmine dose-dependently produced an anti-allodynic 
effect and pretreatment with the muscarinic antagonist, 
pirenzepine, significantly diminished the anti-allodynic effect 
of the neostigmine-CHA combination. Therefore, spinal 
muscarinic stimulation may modulate the transmission of 
afferent allodynic information. 
    Adenosine also modulates nociceptive transmission in the 
spinal cord. Both A1 and A2 subtypes of adenosine receptors 
are present in the substantia gelatinosa of the spinal dorsal 
horn [22,23]. Although adenosine A2 agonists have no anti-
nociceptive effect, adenosine A1 receptors produce anti-
nociception in the spinal cord [5]. Adenosine A1 receptor 
agonists attenuated not only postoperative hyperalgesia 
but also mechanical allodynia [4,6]. Spinal adenosine 
receptor stimulation can have anti-allodynic activity by 
presynaptic inhibition of excitatory neurotransmitter release 
[24], postsynaptic inhibition of the effects of excitatory 
neurotransmitters [25], and spinal norepinephrine release 
leading to analgesia by α 2-adrenoceptors [26]. These results 
suggest that adenosine receptor agonists can modulate 
the underlying spinal hyperexcitability state involved in 
neuropathic pain. 
    Chiari and Eisenach [6] reported that IT neostigmine interacted 
synergistically with adenosine to reduce postoperative hyper-
sensitivity, reflecting an adrenergic component of adenosine 
mechanism of action in the postoperative model. Spinal adeno-
sine A1 receptor activation induced dorsal horn norepine  phrine 
release, ultimately leading to analgesia by an α 2-adrenoceptor 
mechanism [27]. IT administration of an α2-adrenoceptor 
agonist, when combined with muscarinic receptor agonist, 
produces a synergistic anti-allodynic effect in the SNL model 
[28]. The antinociceptive action of adenosine A1 receptor 
agonists results from inhibition of excitatory neurons such as 
substance P or NMDA [29], whereas cholinesterase inhibitors 
regulate the GABA inhibitory system [20]. Therefore, our results 
may reflect both an adrenergic component of adenosine activity 
as well as other interactions between cholinesterase inhibitors 
and adenosine A1 receptor agonists.
    The antiallodynic effects of intrathecally co-administered 
drugs may be mediated by independent receptor systems 
and there was a significant dose reduction of each drug. 
Synergism usually indicates that two drugs have different final 
pathways to produce their effects, but can also result from a 
decreased clearance, changes in agonist affinity, and functional 
interactions. The duration of activity was not changed in the 
combination group, suggesting there was no change in the 
clearance of either drug. Changes in agonist affinity can be 
reflected by changes in slopes of dose-response curves [30]. 
Here, the slope was increased and shifted to the left in the 
combination group (Fig. 1). Functional receptor interactions 
should increase the appearance of sedation and motor 
weakness as well as the allodynic component, but this was not 
observed, excluding a facilitation of receptor interactions (Table 3). 
    Pretreatment with pirenzepine, a muscarinic antagonist, 
signi  ficantly reduced the maximal effect of neostigmine-CHA 
combination. We chose pirenzepine because its antagonistic 
effect was most effective in the reversal of mechanical allodynia 
by IT neostigmine in the SNL model [3]. This finding suggests 
Table 3. Incidence of Side Effects
Agent Dose (μg) 
Number 
of rat
Side effect (%)
Motor weakness Sedation
Neo
CHA
Neo-CHA
0.3
1
3
10
 0.03
0.1
0.3
1
3
0.05 + 0.01
0.10 + 0.03
0.19 + 0.05
  6
  6
  7
  4
10
10
10
  6
  6
10
10
10
-
-
-
1 (25)
-
-
-
-
1 (17)
-
-
-
-
1 (17)
3 (43)
2 (50)
-
-
1 (10)
1 (17)
1 (17)
-
1 (10)
1 (10)
CHA: N
6-cyclohexyladenosine, Neo: neostigmine, Neo-CHA: com-
bination of neostigmine and N
6-cyclohexyladenosine.44 www.ekja.org
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that the spinal cholinergic system is necessary for a synergistic 
anti-allodynic interaction between IT neostigmine and CHA. 
    Although not quantified systematically, IT neostigmine or 
CHA dose-dependently reduced spontaneous activity. Some 
rats showed a mild to moderate degree of side effects, but none 
of them showed severe sedation or motor weakness, and it was 
difficult to measure the degree of drug interaction on side effect 
profiles (Table 3). 
    In conclusion, intrathecally administered neostigmine or CHA 
produced a dose-dependent anti-allodynia without severe side 
effects. IT co-administration of neostigmine and CHA showed a 
synergistic anti-allodynic effect on allodynia after nerve ligation 
injury. 
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